PeptideWell-studiedMelanocortin

PT-141 (Bremelanotide)

Typical dose

0.5–2 mg

~45 min before, as needed · SubQ

Half-life

2-3 hours

What is PT-141 (Bremelanotide)?

Melanocortin receptor agonist originally developed for sexual dysfunction. Acts centrally on the brain, not vascularly like PDE5 inhibitors.

Agonizes MC3R and MC4R in the brain, stimulating sexual arousal pathways.

Common uses: Sexual desire, arousal, erectile function in both sexes.

Typical dose: Typical: 0.5–2 mg SubQ, ~45 min before activity, as needed (not daily).
Protocol notes: 1-2mg SubQ as needed. Max 1 dose per 24h.

2-3 hours

Nausea (common), facial flushing, transient BP increase, headache.

Preparation: Mix a 10 mg vial with 2 mL bac water → 5 mg/mL. A 1 mg dose = 0.2 mL = 20 units.
Reconstitution: Reconstitute a 10 mg vial with 2 mL BAC water → 5 mg/mL. A 1 mg dose = 0.2 mL = 20 units on a U-100 syringe.
Storage: Refrigerate pens or vials per manufacturer. Protect from light.

with Melanotan II
Caution · moderate
Both target melanocortin receptors. Stacking amplifies nausea, flushing, and prolonged erections (priapism risk in men).
Timing: Separate by at least 24 hours; do not co-administer
with Melanotan II
Caution · moderate
PT-141 (Bremelanotide) is derived directly from Melanotan II. Using both simultaneously gives no additional benefit and significantly increases nausea, flushing, spontaneous erections, and blood pressure elevation.
Timing: Do not use both; choose one. PT-141 is derived from Melanotan II.
with Tadalafil
Caution · mild
Both compounds lower blood pressure via different mechanisms (MC4R vs PDE5). Combined use can cause significant hypotension — start with minimal doses and assess tolerance individually before combining.
Timing: Use lowest effective doses; monitor blood pressure; do not combine with alcohol
with BPC-157
Compatible
BPC-157 (healing/gut repair) and PT-141 (sexual function/MC4R agonist) act on entirely different receptor systems with no known pharmacological interaction.
Timing: Independent injection timing; no pharmacological conflict
with BPC-157
Compatible
No known interaction. PT-141 (Bremelanotide) activates melanocortin receptors for sexual arousal; BPC-157 for systemic healing and inflammation. Complementary use in optimization protocols.
Timing: Administer separately; PT-141 subcutaneous 1–2h before, BPC-157 as scheduled

Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.